FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

NECLIFE

22.35
+0.15 (0.68%)
Updated 03:28 04/08 IST

NECLIFE Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for NECLIFE
Disclaimer
0% Bullish
0% Bearish

NECLIFE Buy or Sell - Brokerage Reports

No. of reports in last year
0
No. of analysts
0
Average Consensus Forecast
Consensus Potential
0.00%
See NECLIFE Share Price Targets >>

NECLIFE Ratings

Long term NECLIFE rating by FrontPage users
0/5 (0 Ratings)0
Find answers to all your questions on live NECLIFE message board: Is NECLIFE buy or sell? Should I buy NECLIFE shares? Why are NECLIFE shares falling? Should I invest in NECLIFE stock?

  1. Home
  2. NECLIFE Forum

NECLIFE Share Price Discussion

P
Reputation: 7,350 • Jul 29 6:13 AM

Type
Buy
Instrument
NECLIFE
Entry Price
₹22.45
Price@Trade
₹22.45
Target Price
₹26
Stop Price
₹19
Valid Till
Jul 29, 2021 3:20 AM
Margin
₹11,225 approx for 500 Qty
Status
Active
Like
Reply
P
Reputation: 7,350 • Jun 18 3:20 AM

Type
Buy
Instrument
NECLIFE
Entry Price
₹26.45
Price@Trade
₹26.45
Target Price
₹32
Stop Price
₹22
Valid Till
Jun 25, 2020 3:20 AM
Margin
₹264,500 approx for 10000 Qty
Status
Exited
Exit Price
₹25.15
Net P&L
-₹13,000 (-4.91%)
Like
Reply (1)
Latest replies
Profit Doubler @ebrahim
Jun 23 4:36 AM

Update
Exited
Exit Price
₹25.15
Net P&L
-₹13,000 (-4.91%)
P
Reputation: 7,350 • Jun 17 7:05 AM

Type
Buy
Instrument
NECLIFE
Entry Price
₹21.25
Price@Trade
₹21.25
Target Price
₹25
Stop Price
₹18
Valid Till
Jun 24, 2020 3:20 AM
Margin
₹106,250 approx for 5000 Qty
Status
Target Achieved
Exit Price
₹25
Net P&L
+₹18,750 (+17.65%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Jun 18 2:47 AM

Update
Target Achieved
Exit Price
₹25
N
Reputation: 4,537 • Apr 14 2:03 AM
Trade Setup for Wednesday: Top 15 things to know before Opening Bell
the key support level for Nifty is placed at 8,900.15, followed by 8,806.45. If the index starts moving up, key resistance levels to watch out for are 9,099.8 and 9,205.75.
Moneycontrol
Like
Reply
N
Reputation: 4,537 • Jan 30 2:43 AM
Coronavirus outbreak: Indian drug makers may see disruption of drug supply chain in coming weeks
India imports about $4.5 billion worth of APIs and KSMs from China. These include antibiotics, hormones, vitamins, anti-hypertension and anti-diabetes drugs.
Moneycontrol
Like
Reply
U
Reputation: 563 • Aug 26, 2019 4:38 AM

NECLIFE - 326711
Fire/ explosion in Unit II of the company at Village Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali) Punjab'.
Like
Reply
N
Reputation: 4,537 • May 27, 2019 5:48 AM
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • NECLIFE - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization383.55
    Enterprise Value1,164.97
    Price to Earnings11.41
    Price to Book Value0.35
    Return on Capital Employed0.09
    Return on Equity0.05
    Face Value1
    Dividend YieldNA
  • NECLIFE Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Aug 422.422.7521.322.25
    Aug 321.322.4520.8522.2
    Jul 3119.8521.418.820.8
    Jul 3021.7521.7520.1520.15
    Jul 2921.522.4521.4522.35
  • NECLIFE Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹20.95
    30 Day Moving Average₹21.74
    50 Day Moving Average₹19.75
    100 Day Moving Average₹15.98
    200 Day Moving Average₹14.49
  • NECLIFE - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue1,8731,643.340.14
    Operating Profit236224.220.05
    Profit Before Tax6367.21-0.06
    Net Income5255.13-0.06
  • NECLIFE - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds1,1041,0580.04
    Total Liabilities1,6001,665-0.04
    Total Assets2,7042,724-0.01
  • NECLIFE - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity65198.62-0.67
    Cash from Investing Activity-29-18.110.6
    Cash from Financing Activity-40-204.12-0.8
    Net Cash Flow-4-23.6-0.83
  • NECLIFE - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.020.02
    Return on Equity0.050.05
    Return on Capital Employed0.090.1
  • NECLIFE - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.14
    3 Year CAGR Growth in Operating Profit-0.12
    3 Year CAGR Growth in EBIDTA-0.16
    3 Year CAGR Growth in Net Income-0.22
    3 Yr CAGR Growth - Diluted EPS-0.21
  • NECLIFE - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.15
    5 Year CAGR Growth in Operating Profit-0.19
    5 Year CAGR Growth in EBIDTA-0.21
    5 Year CAGR Growth in Net Income-0.39
    3 Yr CAGR Growth - Diluted EPS-0.39
  • NECLIFE - Recent News

    keyboard_arrow_down
    NewsBot
    Apr 14 2:03 AM
    Trade Setup for Wednesday: Top 15 things to know before Opening Bell
    Moneycontrol
    NewsBot
    Jan 30 2:43 AM
    Coronavirus outbreak: Indian drug makers may see disruption of drug supply chain in coming weeks
    Moneycontrol
    NewsBot
    May 27, 2019 5:48 AM
    NewsBot
    Feb 11, 2019 11:22 AM
    NewsBot
    Nov 15, 2018 6:57 AM
  • NECLIFE - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020